Latest news and press releases about Cullinan Therapeutics, Inc. (CGEM): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in pat...
Price
| Price | $20.63 |
| Market Cap | $1.3B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.94 |
| EV / EBITDA | -6.15 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -52.89% |
| Return on Invested Capital | -68.50% |
| Return on Assets | -56.27% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADCT · BCYC · CBLL · EHAB · LAB · NMRA · OMER
Explore sector: Healthcare · Biotechnology
More sections of CGEM: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks